Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0257


Potential clinical implications of Next-Generation Sequencing in Liver, Billiary, and Pancreatic cancer.

Demosthenes Ziogas, MD, PhD 1, 2.

Affiliation: Demosthenes Ziogas MD, PhD,
1Department of Surgery, 'G. Hatzikosta' General Hospital, Ioannina 45001, Greece
2Centre for Biosystems and Synthetic Genomic Network Medicine Center – CBS.GenNetMed Ioannina University, Ioannina, Greece.


Adenocarcinoma of Hepatic, Billiary, and Pancreas (HBP) has a grim prognosis. Analysis of cancer-related death of the U.S.A. Surveillance, Epidemiology, and End Results program (SEER) over the past decades lets modest optimism for changing the poor outcome if current therapeutic strategy design will be continued. These unmet clinical needs reflect too slow progress in understanding tumorigenesis, metastasis as well as primary and acquired therapeutic resistance. This lack of precise targeting of molecular mechanisms underlying drug resistance explain multiple negative randomized controlled trials (RCTs) with exception of recorafenib a new targeted drug in the treatment of advanced hepatocellular carcinoma (HCC).
Rapid refinement and validity of next-generation sequencing (NGS) create exciting expectations for identifying cancer driver genes and druggable mutational landscape. In this review, NGS including targeted NGS, whole exome sequencing (WES) and whole genome sequencing (WGS) are analyzed and discussed. Moreover, potential and challenges for detection of robust biomarkers and novel drug discovery based on the identification of new oncotargets are extensively described.

(Citation: Gastric & Breast Cancer 2017; 12(1): 31-66)



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 25 February 2017